In the newly created role, Yellin will be responsible for identifying and supporting both organic and inorganic initiatives to drive the company’s growth objectives. He will lead the development of the overall corporate strategy, as well as Cantel Medical’s acquisition program.
“During Seth’s seven years of service at Cantel, he has made significant contributions to the overall execution of our corporate strategy and has deep knowledge of all our businesses,” president and CEO George Fotiades said in a news release. “We see enormous untapped potential in our core markets representing the opportunity to drive strong organic growth in all our major business segments. We are committed to bringing the right resources and leadership to ensure our realization of these important endeavors and are excited to put Seth in a position to help Cantel take advantage of these important growth drivers.”
Yellin has more than 20 years of corporate strategy, business development and investment experience. He previously served as executive VP of strategy and corporate development for Cantel medical.